MISSISSAUGA, Ontario, March 8, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (OTC Bulletin Board : CGNH ) announced today that it is making available to its common stockholders and Series 2 Class B common stockholders a "Stockholder Questionnaire," which the Company hopes will assist it in obtaining an accurate share count of the Company's shares currently held in "street name" through brokers, banks or other nominees.
If you have not received the Stockholder Questionnaires via mail, you can download copies of the questionnaires from the "Investor Relations" section of the Company's website (www.cardiogenics.com). We urge all stockholders to take the time to complete and return the applicable questionnaire to the Company as soon as possible. The questionnaires contain the mailing address, fax number and e-mail address, which can be used by stockholders for returning their completed questionnaires.
Any inquiries regarding the questionnaires can be directed to Creative Capital and Trading, Inc., which is assisting the Company in this matter:
Creative Capital and Trading, Inc.
Attention: Tony Forte – Tel: 732-751-1947 or
Jeff Goss – Tel: 732-556-6924
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.
Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.
SOURCE CardioGenics Holdings Inc.